These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 30638612)

  • 1. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.
    Puwanant A; Isfort M; Lacomis D; Živković SA
    Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
    Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
    Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
    Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
    Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
    Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
    J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.
    Kao JC; Brickshawana A; Liewluck T
    Curr Neurol Neurosci Rep; 2018 Aug; 18(10):63. PubMed ID: 30078154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
    Cham J; Ng D; Nicholson L
    J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series.
    Wong EYT; Yong MH; Yong KP; Tan EH; Toh CK; Kanesvaran R; Takano A; Ng QS
    Asia Pac J Clin Oncol; 2021 Oct; 17(5):e262-e267. PubMed ID: 32985078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
    Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
    Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.
    Nelke C; Pawlitzki M; Kerkhoff R; Schroeter CB; Aktas O; Neuen-Jacob E; Polzin A; Meuth SG; Ruck T
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37884388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
    Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
    BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
    Johansen A; Christensen SJ; Scheie D; Højgaard JLS; Kondziella D
    Neurology; 2019 Apr; 92(14):663-674. PubMed ID: 30850443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.
    Kang KH; Grubb W; Sawlani K; Gibson MK; Hoimes CJ; Rogers LR; Lavertu P; Yao M
    Am J Otolaryngol; 2018; 39(5):642-645. PubMed ID: 29903623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of myasthenia gravis and myositis induced by pembrolizumab].
    Noda T; Kageyama H; Miura M; Tamura T; Ito H
    Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
    Moreira A; Loquai C; Pföhler C; Kähler KC; Knauss S; Heppt MV; Gutzmer R; Dimitriou F; Meier F; Mitzel-Rink H; Schuler G; Terheyden P; Thoms KM; Türk M; Dummer R; Zimmer L; Schröder R; Heinzerling L
    Eur J Cancer; 2019 Jan; 106():12-23. PubMed ID: 30453170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report.
    Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G
    BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
    Fazal M; Prentice DA; Kho LK; Fysh E
    Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
    Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
    ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis.
    Xu M; Nie Y; Yang Y; Lu YT; Su Q
    Neurologist; 2019 May; 24(3):75-83. PubMed ID: 31045716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
    Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
    Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.